US equities |
SPCX $162.56 ▲+9.99% MU $913.79 ▲+1.98% TSLA $387.67 ▲+3.74% NVDA $221.18 ▲+2.18% SNDK $1,386.75 ▲+1.57% META $709.80 ▲+2.24% GOOGL $333.59 ▼-1.96% AAPL $344.06 ▲+1.34%
FinancialContent

Instinct Bio Technical Company Holdings Inc. - Common stock (NQ:BIOT)

0.2021 -0.0187 (-8.47%)
Delayed Quote Updated: 12:59 PM EDT, Oct 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 562,616
Open 0.2210
Bid (Size) 0.2021 (100)
Ask (Size) 0.2025 (200)
Prev. Close 0.2208
Today's Range 0.2011 - 0.2299
52wk Range 0.2120 - 50.00
Shares Outstanding 8,024,092
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Instinct Bio Returns to Profit and Grows Revenue Nearly 10% in Yen Terms in First Half of Fiscal 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Regulatory Compliance
News headline image
BIOT Named Authorized Representative for IN01 Cancer Immunotherapy in Japan and China
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire

Performance

52-Week Range 99.6% below 52-week high
0.2021
0.2152W Low 50.0052W High
1 Week 44.8% below 1-week high
0.211W Low 0.371W High

Instinct Bio Technical Company Holdings Inc. - Common stock (BIOT) traded between $0.21 and $50.00 over the past 52 weeks and last traded at $0.20, 99.6% below its 52-week high. Over the past week it ranged between $0.21 and $0.37.

Past 12 Months
-37.8%
-54.5%
-98.7%
-98.7%
-98.7%
-98.7%
1W -$0.12
1M -$0.24
3M -$15.30
6M -$15.30
YTD -$15.30
1Y -$15.30

BIOT was -98.7% over the past year, -98.7% over six months, -98.7% year to date, -37.8% in the last week.

12 Months vs Market
BIOT
-98.7%
DIA
+12.7%
SPY
+15.2%
QQQ
+18.9%
IWM
+11.6%

Over the past 12 months BIOT returned -98.7% versus DIA (Dow) +12.7%, SPY (S&P 500) +15.2%, QQQ (Nasdaq 100) +18.9% and IWM (Russell 2000) +11.6%.

Volume & Liquidity 0.79× 3-mo avg
Today 562,616 3-mo avg 709.1K
1W
633.3K
1M
464.7K
3M
709.1K
6M
709.1K
YTD
709.1K
1Y
709.1K

BIOT most recently traded 562,616 shares against a 3-month average daily volume of 709.1K.

More News

Read More
News headline image
Instinct Bio Receives Nasdaq Notifications Regarding Minimum Bid Requirement and Minimum Market Value of Listed Securities and Publicly Held Shares
Via NewMediaWire
News headline image
INSTINCT BIO Provides Operational Update on Indonesia Growth Platform and Product Development Initiatives
From Instinct Bio Technical Company Holdings Inc.
Via GlobeNewswire
News headline image
Instinct Bio Announces Strategic Collaboration with PT PARVA CANDELA to Develop Cosmetics Business in Indonesia
From Instinct Bio Technical Company Holdings Inc.
Via GlobeNewswire
News headline image
Instinct Bio Announces Strategic Collaboration With INVITRX to Expand GENREVER Into U.S. and Advance Indonesia Regenerative Medicine Initiatives
Via NewMediaWire
News headline image
Blade Therapeutics to Participate in “Drug Development in Pulmonary Medicine” Panel Discussion at 2022 BTIG Biotechnology Conference
From Blade Therapeutics, Inc.
Via Business Wire
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗
Via InvestorPlace
News headline image
Blade Therapeutics Presents Preclinical Data Highlighting Differentiating Characteristics of Cudetaxestat at the American Thoracic Society 2022 International Conference
From Blade Therapeutics, Inc.
Via Business Wire
News headline image
Blade Therapeutics Presents Data from Phase 1 and Preclinical Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference
From Blade Therapeutics, Inc.
Via Business Wire
News headline image
Blade Therapeutics Announces Feedback from FDA on End-of-Phase 1 Data Package
From Blade Therapeutics, Inc.
Via Business Wire
News headline image
Blade Therapeutics to Present Data from Preclinical and Phase 1 Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference
From Blade Therapeutics, Inc.
Via Business Wire
News headline image
Blade Therapeutics Announces Successful Completion of Phase 1 Clinical Study that Evaluated Co-Administration of Cudetaxestat with Either of Two Approved Therapies for Idiopathic Pulmonary Fibrosis
From Blade Therapeutics, Inc.
Via Business Wire

Frequently Asked Questions

Is Instinct Bio Technical Company Holdings Inc. - Common stock publicly traded?
Yes, Instinct Bio Technical Company Holdings Inc. - Common stock is publicly traded.
What exchange does Instinct Bio Technical Company Holdings Inc. - Common stock trade on?
Instinct Bio Technical Company Holdings Inc. - Common stock trades on the Nasdaq Stock Market
What is the ticker symbol for Instinct Bio Technical Company Holdings Inc. - Common stock?
The ticker symbol for Instinct Bio Technical Company Holdings Inc. - Common stock is BIOT on the Nasdaq Stock Market
What is the current price of Instinct Bio Technical Company Holdings Inc. - Common stock?
The current price of Instinct Bio Technical Company Holdings Inc. - Common stock is 0.2021
When was Instinct Bio Technical Company Holdings Inc. - Common stock last traded?
The last trade of Instinct Bio Technical Company Holdings Inc. - Common stock was at 10/21/26 12:59 PM ET
What is the market capitalization of Instinct Bio Technical Company Holdings Inc. - Common stock?
The market capitalization of Instinct Bio Technical Company Holdings Inc. - Common stock is 1.62M
How many shares of Instinct Bio Technical Company Holdings Inc. - Common stock are outstanding?
Instinct Bio Technical Company Holdings Inc. - Common stock has 2M shares outstanding.